CytoDyn Inc. (CYDY)
| Market Cap | 256.12M -20.7% |
| Revenue (ttm) | n/a |
| Net Income | -40.28M |
| EPS | -0.04 |
| Shares Out | 1.37B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,364,308 |
| Open | 0.1875 |
| Previous Close | 0.1865 |
| Day's Range | 0.1829 - 0.1880 |
| 52-Week Range | 0.1829 - 0.3970 |
| Beta | 1.21 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 11, 2026 |
About CytoDyn
CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications. It is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19. The company’s leronlimab is currently under phase 2 development for the treatment of micro-satellite stable colorectal cancer, and solid tumors in oncology, such as metastatic triple-negative breast cancer. It has a collaboration with Creatv Bio. The company was ... [Read more]
Financial Performance
Financial StatementsNews
CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer's Disease
Phase 2a study will evaluate the safety and biological activity of leronlimab in patients over the age of 50 with early-stage, biomarker-confirmed Alzheimer's disease VANCOUVER, Washington, June 11, 2...
Natera, CytoDyn collaborate to advance ctDNA-guided development
Natera (NTRA) and CytoDyn Inc. (CYDY) announced a strategic collaboration to evaluate circulating tumor DNA dynamics and generate real-world molecular insights to support CytoDyn’s metastatic colorect...
CytoDyn Transcript: 16th Annual LD Micro Invitational Conference
Leronlimab is advancing through phase II trials in colorectal cancer, with rapid enrollment and promising early ctDNA and tumor response data. Retrospective results in triple-negative breast cancer are strong, and new studies are planned. Large market opportunities and regulatory milestones are targeted in 2024.
CytoDyn to Present at the LD Micro Invitational XVI
CFO Robert E. Hoffman to deliver company presentation on May 18 at 10 a.m.
CytoDyn Transcript: Study update
The CLOVER Phase II study in metastatic colorectal cancer shows promising early results, with all patients experiencing ctDNA declines and most achieving tumor shrinkage or stable disease. Leronlimab showed a strong safety profile and potential efficacy, even in KRAS-mutant cases. Upcoming milestones include expanded access in breast cancer and new trials.
CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer
Program provides access to leronlimab for patients with limited treatment options while supporting ongoing clinical development
CytoDyn to Host Investor Webcast
VANCOUVER, Washington, April 23, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized mo...
CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026
Ongoing Phase 2 study in metastatic colorectal cancer (mCRC) demonstrates early clinical and biomarker activity with leronlimab in combination with TAS-102 and bevacizumab, supporting CCR5 as a therap...
CytoDyn Registration statement: Registration filing
CytoDyn filed a registration statement on April 22, 2026, providing details about a securities offering with the SEC.
CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study
Enrollment concludes with just over 60 patients participating across seven clinical sites located throughout the United States
CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026
Translational study in metastatic triple-negative breast cancer (mTNBC) shows leronlimab-mediated CCR5 inhibition induces PD-L1 expression, modulates immune checkpoint signaling, and is associated wit...
CytoDyn to Present at the AACR Annual Meeting 2026
VANCOUVER, Wash., April 14, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclo...
CytoDyn Quarterly report: Q3 2026
CytoDyn has published its Q3 2026 quarterly earnings report on April 8, 2026.
CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer
Preclinical data demonstrates leronlimab-mediated CCR5 inhibition enhances Temozolomide and radiation response in Glioblastoma
CytoDyn closes $17.5M financing for leronlimab development
CytoDyn (CYDY) has closed on a financing of $17.5M in gross proceeds, with Paulson Investment Company acting as placement agent. Net proceeds from the financing will primarily support the advancement…
CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab
VANCOUVER, Washington, March 05, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized mo...
CytoDyn announces new data on leronlimab’s treatment of mTNBC
CytoDyn (CYDY) announced that new preclinical, translational, and clinical data supporting leronlimab’s proposed role in the treatment of metastatic triple-negative breast cancer, mTNBC, was presented...
CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference
Leronlimab-mediated CCR5 blockade modulates T-Cell exhaustion pathways and PD-L1 Biology relevant to ICI response Durable Clinical Observations and Favorable Safety Profile Observed in Heavily Pretrea...
CytoDyn announces benefactor committed funding to support EAP
CytoDyn (CYDY) announced that a benefactor has formally committed funding to support the Company’s Expanded Access Program, EAP, for patients with triple-negative breast cancer. “We are honored by thi...
CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer
VANCOUVER, Washington, Jan. 27, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized mon...
CytoDyn Quarterly report: Q2 2026
CytoDyn has published its Q2 2026 quarterly earnings report on January 9, 2026.
CytoDyn releases 2025 December letter to shareholders
CEO Jacob Lalezari released the following letter: “As we close out the year and step with confidence and purpose into 2026, I want to extend my sincere appreciation for your…
December 2025 Letter to Shareholders
VANCOUVER, Washington, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As we close out the year and step with confidence and purpose into 2026, I want to extend my sincere appreciation for your s...
CytoDyn announces findings on PD-L1 survival in triple-negative breast cancer
CytoDyn (CYDY) announced that breast cancer specialist and medical oncologist, Milana V. Dolezal, MD, MSci, is presenting a poster entitled “Prolonged survival following PD-L1/PD-1 immune checkpoint i...
CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium
Leronlimab treatment is associated with upregulation of PD-L1 in circulating tumor cells and cancer-associated macrophage-like cells